Related Experiment Video
Updated: Mar 1, 2026

In situ Subcellular Fractionation of Adherent and Non-adherent Mammalian Cells
Published on: July 23, 2010
Calcein represses human papillomavirus 16 E1-E2 mediated DNA replication via blocking their binding to the viral
Dipon Das1, Nathan W Smith1, Xu Wang1
1VCU Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry, Department of Oral and Craniofacial Molecular Biology, Richmond, VA 23298, USA.
Abstract:
Human papillomaviruses are causative agents in several human diseases ranging from genital warts to ano-genital and oropharyngeal cancers. Currently only symptoms of HPV induced disease are treated; there are no antivirals available that directly target the viral life cycle. Previously, we determined that the cellular protein TopBP1 interacts with the HPV16 replication/transcription factor E2. This E2-TopBP1 interaction is essential for optimal E1-E2 DNA replication and for the viral life cycle. The drug calcein disrupts the interaction of TopBP1 with itself and other host proteins to promote cell death. Here we demonstrate that calcein blocks HPV16 E1-E2 DNA replication via blocking the viral replication complex forming at the origin of replication. This occurs at non-toxic levels of calcein and demonstrates specificity as it does not block the ability of E2 to regulate transcription. We propose that calcein or derivatives could be developed as an anti-HPV therapeutic.
Insights
The drug calcein blocks human papillomavirus (HPV) DNA replication by disrupting essential protein interactions. This finding suggests calcein as a potential therapeutic for HPV infections.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- Human papillomaviruses (HPV) cause diseases like cancer, with no direct antivirals targeting their life cycle.
- The cellular protein TopBP1 interacts with HPV16 E2, crucial for viral DNA replication.
- Current treatments only manage HPV disease symptoms, not the virus itself.
Purpose of the Study:
- To investigate if the drug calcein can inhibit HPV16 DNA replication.
- To determine if calcein's effect on HPV replication is specific and occurs at non-toxic levels.
Main Methods:
- Studying the interaction between HPV16 E2 and TopBP1.
- Assessing calcein's impact on HPV16 E1-E2 DNA replication in vitro.
- Evaluating calcein's effect on E2-mediated transcription.
Main Results:
- Calcein effectively blocks HPV16 E1-E2 DNA replication at the origin of replication.
- The drug functions at non-toxic concentrations.
- Calcein specifically inhibits replication without affecting E2's transcriptional regulation.
Conclusions:
- Calcein disrupts the formation of the viral replication complex.
- Calcein demonstrates potential as a novel antiviral therapeutic agent against HPV.
- Calcein or its derivatives could be developed for treating HPV-induced diseases.
More Related Videos
Related Concept Videos
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
Negative Regulator Molecules
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
DNA Helicases
Restarting Stalled Replication Forks

